License Agreement among Intellect and AHP MANUFACTURING BV, acting through its Wyeth Medica Ireland Branch and ELAN PHARMA INTERNATIONAL LIMITED (ANTISENILIN)
In May, 2008, we entered into a License Agreement (the “Agreement”) by and among Intellect and AHP MANUFACTURING BV, acting through its Wyeth Medica Ireland Branch, (“Wyeth”) and ELAN PHARMA INTERNATIONAL LIMITED (“Elan”) to provide Wyeth and Elan (the “Licensees”) with certain license rights under certain of our patents and patent applications (the “Licensed Patents”) relating to certain antibodies that may serve as potential therapeutic products for the treatment for Alzheimer’s Disease (the “Licensed Products”) and for the research, development, manufacture and commercialization of Licensed Products.
Pursuant to the Agreement, we granted the Licensees a co-exclusive license (co-exclusive as to each Licensee) under the Licensed Patents to research, develop, manufacture and commercialize certain Products in the Field in the Territory (all as defined in the Agreement) and a non-exclusive license under the Licensed Patents to research, develop, manufacture and commercialize certain other Licensed Products (other than Bapineuzumab Products) in the Field in the Territory. We received $1 million as of June 30, 2008 and an additional $1 million in August, 2008 pursuant to this Agreement. In addition, we are eligible to receive certain milestones and royalties based on sales of Licensed Products as set forth in the Agreement. . http://ir.stockpr.com/intellectns/sec-filings/content/0001144204-08-061891/v131146_10ksb-a.htm?TB_iframe=true&height=auto&width=auto&preload=false
Market Data 
Markets 
AI
